Replies to post #250317 on Avid Bioservices Inc (CDMO)

[Protector]

cj, I have been thinking about what you wrote:

...what gets me about Dr. Birge is that this man's cancer lab of 10 or so at Rutgers has been working on “the eradication of cancer” for ~15yrs, and all of a sudden he hooks up with Dr. Brekken & Peregrine, and now he's heading to Istalbul in June to give a talk ICHC 2016, and this is the subject he chooses: “Phosphatidylserine is a Global Immunosuppressive Signal in Cell Death & Cancer”.

I had never looked at it that way because I wasn't very, or actually not, informed about what Dr. Birge has been doing the past 15yrs.

I'd like however, with hindsight and all the info we have received here on the IHub PPHM board, wonder more in depth about the WHY but also the HOW.

I think, and possibly RRDog can confirm that, that Dr. Birge as well as Rutgers have an iron reputation. That means that Dr. Birge when he, apparently, starts a road show that started in faculty then followed by some public appearances (e.g. PPHM's conference/round table) and now on the public forum at the ICHC 2016 and with the SAME TITLE “Phosphatidylserine is a Global Immunosuppressive Signal in Cell Death & Cancer” does NOT do such thing without FOR HIMSELF done the needed research to support his claims.

He will for sure have been in contact with Dr. Thorpe and Dr. Brekken because it is unthinkable that Dr. Bridge di, say, in one or two years all the needed research to make these claims on his own. Thorpe and Brekken have complete labs working on this.

This actually implies that Dr. Birge may have been involved in this from BEFORE CEO King mentioned his couple of dozen collaborations. As I wrote before, if you mention the collaborations they exist on, hence some before, the moment you can mention them as a fact.

And, Dr. Birge, as many others all of us included, will certainly be aware of the PII dose switching debacle and apparently just like Dr. Garnick must have gien it no more weight then just a bump in the road (as Garnick told us personally on a past annual meeting mingling). Dr. Birge must, just as Dr. Brekken confirmed at NYAS two years ago, have know that the PII results where BETTER then those presented on 7th Sept 2012.

A little detail, Dr. Birge uses CEO King's terminology (Global vs local) vs Brekken's (Upstream vs downstream). I'd propose 'Systemic' :) but then again, Hunt Managers have no say in that :)

By looking at all this in the above presented way, I think that Dr. Birge involvement is/will be much more important then we think. The man has something to loose by being wrong: his reputation.

Furthermore he is clearly on a mission here because as you emphasized he is taking his message out on the international forum.

Now what are the chances that in the same period of time another cancer research heavy weight, Dr. Wolchok from Memorial Sloan Kettering, with as much to loose at Dr. Brige, also embraces Phophotidylserine (PS) related research and clinical trials. Memorial Sloan Kettering has now officially been mentioned as the Early State Triple Native Breast Cancer clinical trial collaborator (Paclitaxel+Bavituximab).

So there must have been some chemistry behind the curtains that now results in world renound cancer researchers not only being pulled by PS related research but also get involved with PPHM and Bavituximab in public.

And of course, these are the new kids in PPHM town so no disrespect for Dr. Thorpe, Brekken, Antonia, Gabrilovich, etc who probably paved or helped pave this road with CEO King, Garnick and the others.

[cjgaddy]

June2015: Dr.Raymond.Birge & Dr.Xianming.Huang (Dr.Rolf.Brekken-Lab) at Gordon Res. Conference in Maine – speaking next to each other in “Consequences of Lipid Alterations” Session on 6-15-15. Peregrine was the only corp. contributor to this conference, specified as, “In Memory of Dr. Philip E. Thorpe.”...

June 14-19, 2015: “Apoptotic Cell Recognition & Clearance”, Gordon Research Conference, Biddeford, ME
Chair: David S. Ucker, Vice Chairs: Peter Henson & Kirsten Lauber
http://www.grc.org/programs.aspx?id=13127
”Moreover, apoptotic cells are potently immunosuppressive, and their clearance occurs in the absence of inflammation. Recognition & inflammatory modulation represent key elements of an innate immunity that discriminates live from effete cells.”
**The only Corp. Sponsor: PEREGRINE PHARM, “Generous financial support from Peregrine Pharmaceuticals is in memory of Dr. Philip E. Thorpe.”
- - - - - - - -
SESSION: “Consequences of Lipid Alterations for Apoptotic Cell Clearance
Discussion Leader: Christopher Gregory (Univ. of Edinburgh, UK)
7:30pm: Ian Dransfield (Univ. of Edinburgh, UK), “Protein S Binding to Apoptotic Cells...”
8:10pm: Dr. Raymond Birge (Rutgers NJMS), “Apoptotic Cell Recognition Receptors, Tyro3/Axl/Mer...”
8:50pm: Dr. Xianming Huang** (UTSW-MC/Dallas, Brekken Lab), “PS-Targeting Antibodies Overcome Tumor Immunosuppression and Synergize with Immune Checkpoint Blockade"
**Dr. Xianming Huang: formerly in Dr. Philip Thorpe's Lab (RIP, Dr. Thorpe, 1951-2013 http://tinyurl.com/l9gqmt5 ), now in Dr. Rolf Brekken's (PPHM SAB) Lab.
http://www.utsouthwestern.edu/labs/brekken/

= = = = = = = = = = = = = =
...Dr. Raymond Birge has authored ~85 scientific publications in molecular & cancer biology. http://www.ncbi.nlm.nih.gov/pubmed/?term=birge+rb
“The Birge laboratory conducts basic science focused on the eradication of cancer.”
http://birgelab.org => http://birgelab.org/biography.html

Dr. Raymond Birge spoke at Peregrine's 11-2015 “Sci. Session” at SITC'15/Maryland ( http://tinyurl.com/pbof95w ); will be the chair in June 2016 of the ICDS'16/Ireland session where Dr. Rolf Brekken (PPHM SAB) is speaking on “Blockade of PS & Immune Activation in Cancer”; and now also speaking in late June'16 at ICHC'16/Istanbul on, “Phosphatidylserine is a Global Immunosuppressive Signal in Cell Death & Cancer”.

3-1-14/Youtube: “Cancer Research” - Dr. Raymond Birge Laboratory, Rutgers http://birgelab.org

Dr. Ray Birge/2:54: "The immune system is very complex and if it can recognize tumors as being foreign to the body, then it can reactivate & eliminate these tumors to treat as a chronic disease, or in some cases eliminate the tumors. One of the projects that our lab is interested in is how to reactivate the immune system toward particular cancers, and we believe that the type of cell death that cancer cells undergo will determine whether or not they'll be an immune reaction against the cancer. If cells die, through a process called apoptosis, in a certain way, they can reactivate / activate the immune system and give a durable, anti-tumor response. The problem that we're trying to understand is how the tumor cells evade the immune system and therefore block these immune-suppressing signals to reactivate the immune system against cancer..."

MORE:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=120059503
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=120060958